Bausch And Lomb Inc Drug Patent Portfolio

Bausch And Lomb Inc owns 9 orange book drugs protected by 40 US patents with Lotemax having the least patent protection, holding only 1 patent. And Xiidra with maximum patent protection, holding 16 patents. Given below is the list of Bausch And Lomb Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10507132 Topical administration method 21 Jun, 2037
Active
US10596107 Ophthalmic suspension composition 23 Dec, 2036
Active
US11357738 Semifluorinated compounds and their compositions 29 Sep, 2036
Active
US11534395 Ophthalmic suspension composition 26 Jan, 2036
Active
US9937075 Apparatus and methods for ocular injection 02 May, 2034
Active
US11058677 LFA-1 inhibitor formulations 18 Dec, 2033
Active
US9636332 Methods and devices for the treatment of ocular diseases in human subjects 08 Nov, 2033
Active
US10058615 Semifluorinated alkane compositions 12 Sep, 2033
Active
US10369117 Compositions comprising mixtures of semifluorinated alkanes 12 Sep, 2033
Active
US10449164 Methods of treating ocular disorders using semifluorinated alkanes 12 Sep, 2033
Active
US10576154 Semifluorinated alkane compositions 12 Sep, 2033
Active
US9085553 LFA-1 inhibitor and methods of preparation and polymorph thereof 25 Jul, 2033
Active
US8927574 Crystalline pharmaceutical and methods of preparation and use thereof 12 Nov, 2030
Active
US9353088 Crystalline pharmaceutical and methods of preparation and use thereof 21 Oct, 2030
Active
US9890141 Crystalline pharmaceutical and methods of preparation and use thereof 21 Oct, 2030
Active
US8293742 Preferential vasoconstriction compositions and methods of use 14 Jul, 2030
Active
US9259425 Compositions and methods for eye whitening 14 Jul, 2030
Active
US11596600 Vasoconstriction compositions and methods of use 27 Jul, 2029
Active
US11833245 Vasoconstriction compositions and methods of use 27 Jul, 2029
Active
US8168655 Compositions and methods for treatment of eye disorders 09 May, 2029
Active
US8367701 Crystalline pharmaceutical and methods of preparation and use thereof 15 Apr, 2029
Active
US9447077 Crystalline pharmaceutical and methods of preparation and use thereof 15 Apr, 2029
Active
US8636713 Methods and devices for drug delivery to ocular tissue using microneedle 02 May, 2027
Active
US8084047 Compositions and methods for treatment of eye disorders 17 May, 2026
Active
US8592450 Compositions and methods for treatment of eye disorders 17 May, 2026
Active
US7314938 Modulators of cellular adhesion 10 Mar, 2025
Active
US8784789 Aqueous liquid preparations and light-stabilized aqueous liquid preparations 13 Jan, 2025
Active
US10124000 Modulators of cellular adhesion 05 Nov, 2024
Active
US7745460 Modulators of cellular adhesion 05 Nov, 2024
Active
US7790743 Modulators of cellular adhesion 05 Nov, 2024
Active
US7928122 Modulators of cellular adhesion 05 Nov, 2024
Active
US9216174 Modulators of cellular adhesion 05 Nov, 2024
Active
US8877168 Aqueous liquid preparations and light-stabilized aqueous liquid preparations 30 Jul, 2023 Expired
US6780877 Acid addition salt of optically active piperidine compound and process for preparing the same 19 Sep, 2019 Expired
US5800807 Ophthalmic compositions including glycerin and propylene glycol 29 Jan, 2017 Expired
US6011020 Nucleic acid ligand complexes 04 Jan, 2017 Expired
US5932462 Multiarmed, monofunctional, polymer for coupling to molecules and surfaces 03 Aug, 2016 Expired
US6051698 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes 19 May, 2015 Expired
US5919455 Non-antigenic branched polymer conjugates 27 Oct, 2013 Expired
US6113906 Water-soluble non-antigenic polymer linkable to biologically active material 27 Oct, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Bausch And Lomb Inc.

Activity Date Patent Number
Patent litigations
Notice of Final Determination -Eligible 02 Jul, 2024 US7314938
Withdrawal of Application for PTE 02 Jul, 2024 US8168655
Withdrawal of Application for PTE 02 Jul, 2024 US8084047
Withdrawal of Application for PTE 02 Jul, 2024 US8592450
Withdrawal of Application for PTE 02 Jul, 2024 US7790743
Maintenance Fee Reminder Mailed 10 Jun, 2024 US8293742
Petition Requesting Trial 15 Mar, 2024 US11596600
Payment of Maintenance Fee, 8th Year, Large Entity 21 Feb, 2024 US9447077
Petition Requesting Trial 15 Feb, 2024 US11833245
Paralegal TD Not accepted 14 Feb, 2024 US7314938
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US11357738
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10449164
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10058615
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10576154
Second letter to regulating agency to determine regulatory review period 08 Feb, 2024 US10369117


Bausch And Lomb Inc's Drug Patent Litigations

Bausch And Lomb Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 05, 2006, against patent number US6113906. The petitioner , challenged the validity of this patent, with RICHARD B. GREENWALD et al as the respondent. Click below to track the latest information on how companies are challenging Bausch And Lomb Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11596600 February, 2024 Pending Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US11833245 January, 2024 Trial Instituted
(13 Aug, 2024)
Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US8293742 November, 2021 Final Written Decision - Appealed
(15 May, 2023)
Eye Therapies, LLC et al. Slayback Pharma LLC et al.
US9259425 November, 2021 Terminated-Settled
(05 Oct, 2022)
Eye Therapies, LLC Slayback Pharma LLC
US10596107 January, 2019 Decision
(18 Jul, 2019)
Mohannad Shawer et al.
US10449164 April, 2018 Decision
(17 Jan, 2019)
Novaliq GmbH
US8877168 June, 2016 Terminated-Settled
(14 Nov, 2016)
Senju Pharmaceuticals Co., Ltd. Mylan Pharmaceuticals, Inc.
US8784789 February, 2016 Terminated-Settled
(31 Aug, 2016)
Senju Pharmaceutical Co. Ltd. Mylan Pharmaceuticals, Inc.
US6113906 October, 2006 Decision
(05 Oct, 2006)
RICHARD B. GREENWALD et al


Bausch And Lomb Inc Drug Patents' Oppositions Filed in EPO

Bausch And Lomb Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 04, 2019, by Allergan, Inc.. This opposition was filed on patent number EP16704744A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP20166312A Feb, 2023 SANDOZ AG Granted and Under Opposition
EP14791646A Mar, 2022 European Oppositions Limited Granted and Under Opposition
EP18209003A Dec, 2020 Sandoz AG Granted and Under Opposition
EP16704744A Sep, 2019 Breuer, Markus Revoked
EP16704744A Sep, 2019 European Oppositions Limited Revoked
EP16704744A Sep, 2019 ALLERGAN, INC. Revoked


Bausch And Lomb Inc's Family Patents

Bausch And Lomb Inc drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 45.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Bausch And Lomb Inc Drug List

Given below is the complete list of Bausch And Lomb Inc's drugs and the patents protecting them.


1. Bepreve

Bepreve is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8784789 Aqueous liquid preparations and light-stabilized aqueous liquid preparations 13 Jan, 2025
(3 months from now)
Active
US8877168 Aqueous liquid preparations and light-stabilized aqueous liquid preparations 30 Jul, 2023
(1 year, 2 months ago)
Expired
US6780877 Acid addition salt of optically active piperidine compound and process for preparing the same 19 Sep, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bepreve's drug page


2. Lotemax

Lotemax is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5800807 Ophthalmic compositions including glycerin and propylene glycol 29 Jan, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax's drug page


3. Lotemax Sm

Lotemax Sm is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10596107 Ophthalmic suspension composition 23 Dec, 2036
(12 years from now)
Active
US11534395 Ophthalmic suspension composition 26 Jan, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotemax Sm's drug page


4. Lumify

Lumify is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8293742 Preferential vasoconstriction compositions and methods of use 14 Jul, 2030
(5 years from now)
Active
US9259425 Compositions and methods for eye whitening 14 Jul, 2030
(5 years from now)
Active
US11596600 Vasoconstriction compositions and methods of use 27 Jul, 2029
(4 years from now)
Active
US11833245 Vasoconstriction compositions and methods of use 27 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumify's drug page


5. Lumify Preservative Free

Lumify Preservative Free is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8293742 Preferential vasoconstriction compositions and methods of use 14 Jul, 2030
(5 years from now)
Active
US9259425 Compositions and methods for eye whitening 14 Jul, 2030
(5 years from now)
Active
US11596600 Vasoconstriction compositions and methods of use 27 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumify Preservative Free's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Macugen

Macugen is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6011020 Nucleic acid ligand complexes 04 Jan, 2017
(7 years ago)
Expired
US5932462 Multiarmed, monofunctional, polymer for coupling to molecules and surfaces 03 Aug, 2016
(8 years ago)
Expired
US6051698 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes 19 May, 2015
(9 years ago)
Expired
US5919455 Non-antigenic branched polymer conjugates 27 Oct, 2013
(10 years ago)
Expired
US6113906 Water-soluble non-antigenic polymer linkable to biologically active material 27 Oct, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Macugen's drug page


7. Miebo

Miebo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10507132 Topical administration method 21 Jun, 2037
(12 years from now)
Active
US11357738 Semifluorinated compounds and their compositions 29 Sep, 2036
(11 years from now)
Active
US10058615 Semifluorinated alkane compositions 12 Sep, 2033
(8 years from now)
Active
US10369117 Compositions comprising mixtures of semifluorinated alkanes 12 Sep, 2033
(8 years from now)
Active
US10449164 Methods of treating ocular disorders using semifluorinated alkanes 12 Sep, 2033
(8 years from now)
Active
US10576154 Semifluorinated alkane compositions 12 Sep, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miebo's drug page


8. Xiidra

Xiidra is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11058677 LFA-1 inhibitor formulations 18 Dec, 2033
(9 years from now)
Active
US9085553 LFA-1 inhibitor and methods of preparation and polymorph thereof 25 Jul, 2033
(8 years from now)
Active
US8927574 Crystalline pharmaceutical and methods of preparation and use thereof 12 Nov, 2030
(6 years from now)
Active
US9353088 Crystalline pharmaceutical and methods of preparation and use thereof 21 Oct, 2030
(6 years from now)
Active
US9890141 Crystalline pharmaceutical and methods of preparation and use thereof 21 Oct, 2030
(6 years from now)
Active
US8168655 Compositions and methods for treatment of eye disorders 09 May, 2029
(4 years from now)
Active
US8367701 Crystalline pharmaceutical and methods of preparation and use thereof 15 Apr, 2029
(4 years from now)
Active
US9447077 Crystalline pharmaceutical and methods of preparation and use thereof 15 Apr, 2029
(4 years from now)
Active
US8084047 Compositions and methods for treatment of eye disorders 17 May, 2026
(1 year, 7 months from now)
Active
US8592450 Compositions and methods for treatment of eye disorders 17 May, 2026
(1 year, 7 months from now)
Active
US7314938 Modulators of cellular adhesion 10 Mar, 2025
(4 months from now)
Active
US10124000 Modulators of cellular adhesion 05 Nov, 2024
(26 days from now)
Active
US7745460 Modulators of cellular adhesion 05 Nov, 2024
(26 days from now)
Active
US7790743 Modulators of cellular adhesion 05 Nov, 2024
(26 days from now)
Active
US7928122 Modulators of cellular adhesion 05 Nov, 2024
(26 days from now)
Active
US9216174 Modulators of cellular adhesion 05 Nov, 2024
(26 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xiidra's drug page


9. Xipere

Xipere is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9937075 Apparatus and methods for ocular injection 02 May, 2034
(9 years from now)
Active
US9636332 Methods and devices for the treatment of ocular diseases in human subjects 08 Nov, 2033
(9 years from now)
Active
US8636713 Methods and devices for drug delivery to ocular tissue using microneedle 02 May, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xipere's drug page